WELCOME to Neurodyn

Neurodyn Inc. is a Canadian biotechnology companywhich identifies, validates and develops natural bioactives for the early treatment of neurological diseases. Based in Charlottetown, Prince Edward Island, the company has developed its BioActives Discovery Engine™ through a combination of:

1) international partners with demonstrated historical knowledge of natural health products,
2) in-house medicinal chemistry capability, and
3) proprietary animal models of neurological disease.

This combination of expertise provides Neurodyn with a unique insight into the discovery, validation and development of new compounds for the treatment of neurological diseases.

CNS CRO (cnscro.com), a wholly-owned contract research subsidiary of Neurodyn, offers specialty neurological Contract Research Services in ALS, Parkinson's disease, Alzheimer's disease, epilepsy, schizophrenia, stroke and cognitive function testing.

NeuroQuest Inc. (neuroquest.ca), a second wholly-owned subsidiary, conducts medicinal chemistry programs for the molecular modification of promising BioActive compounds.

iRMBR ("i remember") is a subsidiary company being established for the commercial development of ND-1062 for Parkinson's patients with dementia.

TECHNOLOGY Overview

A robust product pipeline has developed from the BioActives Discovery Engine™, including:

ND-1004

More information coming soon
a treatment for early stage Parkinson’s which has demonstrated in vivo pre-clinical efficacy in acute (MPTP based) models as well as Neurodyn’s proprietary chronic model of Parkinson's disease. more

ND-1062

a clinic-ready validated BioActive with the potential to significantly preserve cognition of Parkinson’s patients with dementia.  This drug candidate is based on an approved BioActive with extensive Phase IV data. more

NQ-1065

a rare first-in-class state-dependent neuromodulator, showing Nav 1.7 specificity, being prepared for a topical orphan status nerve pain condition. This NCE is based on in vivo and human clinic validated natural BioActives.  more

ND-602

a novel therapeutic demonstrating in vivo pre-clinical efficacy in ALS, PD, Alzheimer's disease and Spinal Muscular Atrophy. The company is in its third year of collaboration (late stage pre-clinical evaluation) with the Michael J. Fox Foundation..  more